Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized Controlled Trial to Evaluate the Strategy of Primary Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma (ADCI002 Study)

NCT01717924 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT01717924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01717924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized Controlled Trial to Evaluate the Strategy of Primary Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma (ADCI002 Study)
Lead sponsor
University Hospital, Lille
Phase
Not applicable
Overall status
Recruiting
Start date
October 31, 2012
Completion date
November 30, 2027
Enrollment
314 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

signet ring cell gastric adenocarcinoma